{"_buckets": {"deposit": "7d3c0a98-5acb-4d6c-9ffa-b7d18afc6e71"}, "_deposit": {"created_by": 18, "id": "3227", "owners": [18], "pid": {"revision_id": 0, "type": "depid", "value": "3227"}, "status": "published"}, "_oai": {"id": "oai:air.repo.nii.ac.jp:00003227", "sets": ["1161"]}, "author_link": ["10234", "10221", "11070", "10235", "10232", "10238", "10230", "6135", "10237", "11071", "9468", "10239", "10231", "10236", "11072", "11073", "9499"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3/4", "bibliographicPageEnd": "109", "bibliographicPageStart": "101", "bibliographicVolumeNumber": "44", "bibliographic_titles": [{"bibliographic_title": "秋田医学"}, {"bibliographic_title": "AKITA JOURNAL OF MEDICINE", "bibliographic_titleLang": "en"}]}]}, "item_10001_description_5": {"attribute_name": "内容記述（抄録）", "attribute_value_mlt": [{"subitem_description": "AIM : To assesse the efficacy and safety of therapy with daclatasvir (DCV) and asunaprevir (ASV) for HCV genotype 1.\nMETHOD : The study population was 253 patients who were enrolled in the Akita hepatitis C study group from 2015 to 2016.　We followed them until 24 weeks after the end of treatment.\nRESULT : The sustained virological response (SVR) at 24 weeks after the end of treatment rates were 84.2%.　In univariate analyses, the Y93 mutation and a history of triple therapy with protease inhibitor reduced the SVR 24 rate.　In multivariate analyses, the Y93H mutation, a history of triple therapy with protease inhibitor, and LC status reduced the SVR 24 rate.　The most frequently reported adverse event was ALT elevation, noted in 25.7% of patients.　10.7% of patients had T-Bil elevation, 7.1% experienced drug rush, 11.5% experienced respiratory symptoms, 10.3% developed a fever, and 7.1% experienced digestive symptom.　Only 9 (3.6%) patients stopped taking the drugs due to drug-related severe adverse events.\nCONCLUSION : DCV and ASV therapy showed a high efficacy and low rate of adverse events.", "subitem_description_type": "Other"}]}, "item_10001_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.20569/00003587", "subitem_identifier_reg_type": "JaLC"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "秋田医学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00009294", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03866106", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "AJIMINE, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "9499", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHSHIMA, Shigetoshi"}], "nameIdentifiers": [{"nameIdentifier": "9468", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "GOTO, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "6135", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KOMATSU, Masafumi"}], "nameIdentifiers": [{"nameIdentifier": "10230", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "NAKANE, Kunio"}], "nameIdentifiers": [{"nameIdentifier": "10231", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAGISAWA, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "10232", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Goto, Mitsuo"}], "nameIdentifiers": [{"nameIdentifier": "11070", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "NAKAJIMA, Kou"}], "nameIdentifiers": [{"nameIdentifier": "10234", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miura, Masato"}], "nameIdentifiers": [{"nameIdentifier": "11071", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "FUNAOKA, Masato"}], "nameIdentifiers": [{"nameIdentifier": "10235", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HOSHINO, Takao"}], "nameIdentifiers": [{"nameIdentifier": "10236", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KURAMITSU, Tomoyuki"}], "nameIdentifiers": [{"nameIdentifier": "10237", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "FUJISHIMA, Yuukou"}], "nameIdentifiers": [{"nameIdentifier": "10238", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "WATANABE, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "10239", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Segawa, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "11072", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inomata, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "11073", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "IIJIMA, Katsunori"}], "nameIdentifiers": [{"nameIdentifier": "10221", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-07-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "akitai44_3_4(101).pdf", "filesize": [{"value": "787.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 787900.0, "url": {"label": "akitai44_3_4(101)", "url": "https://air.repo.nii.ac.jp/record/3227/files/akitai44_3_4(101).pdf"}, "version_id": "8152508c-aee3-4648-b824-1e91e8d90e43"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "hepatitis C virus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "interferon free", "subitem_subject_scheme": "Other"}, {"subitem_subject": "daclatasvir", "subitem_subject_scheme": "Other"}, {"subitem_subject": "asunaprevir", "subitem_subject_scheme": "Other"}, {"subitem_subject": "α fetoprotein", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1"}]}, "item_type_id": "10001", "owner": "18", "path": ["1161"], "permalink_uri": "https://doi.org/10.20569/00003587", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-07-05"}, "publish_date": "2018-07-05", "publish_status": "0", "recid": "3227", "relation": {}, "relation_version_is_last": true, "title": ["EFFICACY AND SAFETY OF TREATMENT WITH DACLATASVIR AND ASUNAPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1"], "weko_shared_id": -1}